Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622739 · ClinicalTrials.gov registry record · Phase 4
Ziprasidone in Pediatric Bipolar Disorder
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT00622739 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 28 participants.
The verdict
NCT00622739, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a 6 week, open-label, blinded-rater, randomized, controlled, pilot study designed to determine the dosing, safety and efficacy of ziprasidone in the treatment of pediatric bipolar disorder (PBD). In this pilot study we are comparing the efficacy of rapid versus slow dose titration of ziprasidone in PBD. The investigators hypothesize that subjects on ziprasidone monotherapy will have a reduction in manic symptoms. Also, the investigators hypothesize that slower titration of ziprasidone will result in lesser side effects which will assist in medication compliance as measured by patient report and pill count.
Interventions
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622739
The ClinicalTrials.gov registry entry for NCT00622739 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone is the first listed.
NCT00622739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622739 about?
NCT00622739 is a clinical study titled "Ziprasidone in Pediatric Bipolar Disorder". This is a 6 week, open-label, blinded-rater, randomized, controlled, pilot study designed to determine the dosing, safety and efficacy of ziprasidone in the treatment of pediatric bipolar disorder (PBD). In this pilot study we are comparing the efficacy of rapid versus slow dose titration of ziprasi...
What is the current status of trial NCT00622739?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2007-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00622739?
The interventions under investigation include: Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00622739?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.